Article

Dr. Sonpavde on long-term outcomes with enfortumab vedotin in urothelial carcinoma

Guru P. Sonpavde, MD, director of the Bladder Cancer Program at Dana-Farber Cancer Institute, and associate professor of Medicine at Harvard Medical School, discusses the 2022 ASCO Annual Meeting abstract, “Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.”

Related Videos
4 experts in this video
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Related Content
© 2025 MJH Life Sciences

All rights reserved.